Jeremy Levin, the incoming chief executive of Teva Pharmaceutical Industries, has set up a team to reexamine the company’s pipeline of brand drugs under development. The team rethinking policy is headed by Dr. Medy Wiener, former head of medical research at Novartis Israel. It is being advised by the head of Teva Innovative Ventures, Dr. Aharon Schwartz. Many of Teva’s drugs under development originate from the $6.5 billion acquisition of U.S. company Cephalon in 2010. Others are being developed by the dozens of startups in which Teva has a stake. More than half have reached the pivotal stage of human clinical testing. The drugs under development are for conditions from diabetes to nervous disorders and cancer.
